| Literature DB >> 29236593 |
Veda N Giri1, Karen E Knudsen1, William K Kelly1, Wassim Abida1, Gerald L Andriole1, Chris H Bangma1, Justin E Bekelman1, Mitchell C Benson1, Amie Blanco1, Arthur Burnett1, William J Catalona1, Kathleen A Cooney1, Matthew Cooperberg1, David E Crawford1, Robert B Den1, Adam P Dicker1, Scott Eggener1, Neil Fleshner1, Matthew L Freedman1, Freddie C Hamdy1, Jean Hoffman-Censits1, Mark D Hurwitz1, Colette Hyatt1, William B Isaacs1, Christopher J Kane1, Philip Kantoff1, R Jeffrey Karnes1, Lawrence I Karsh1, Eric A Klein1, Daniel W Lin1, Kevin R Loughlin1, Grace Lu-Yao1, S Bruce Malkowicz1, Mark J Mann1, James R Mark1, Peter A McCue1, Martin M Miner1, Todd Morgan1, Judd W Moul1, Ronald E Myers1, Sarah M Nielsen1, Elias Obeid1, Christian P Pavlovich1, Stephen C Peiper1, David F Penson1, Daniel Petrylak1, Curtis A Pettaway1, Robert Pilarski1, Peter A Pinto1, Wendy Poage1, Ganesh V Raj1, Timothy R Rebbeck1, Mark E Robson1, Matt T Rosenberg1, Howard Sandler1, Oliver Sartor1, Edward Schaeffer1, Gordon F Schwartz1, Mark S Shahin1, Neal D Shore1, Brian Shuch1, Howard R Soule1, Scott A Tomlins1, Edouard J Trabulsi1, Robert Uzzo1, Donald J Vander Griend1, Patrick C Walsh1, Carol J Weil1, Richard Wender1, Leonard G Gomella1.
Abstract
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29236593 PMCID： PMC6075860 DOI： 10.1200/JCO.2017.74.1173
Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544